- Sensex on the BSE increased by 0.03% to 75,442, while Nifty on the NSE increased by 0.7% to 22,982.
- Vodafone Idea’s rating was upgraded by UBS from Neutral to Buy, with a new price target of ₹18.
- Hindudalco Industries had a 0.92% increase in total net profit to ₹3,174 crore over the prior year.
Sensex on the BSE increased by 0.03% to 75,442, while Nifty on the NSE increased by 0.7% to 22,982. TCS, Apollo Hospitals, Hero MotoCorp, ITC, and Sun Pharma were the biggest laggards in the Nifty50 pack, while BPCL, Ultratech Cement, Adani Enterprises, L&T, and Bharti Airtel were the top gainers.
Following a 4% rise in the first trading on the NSE, Vodafone Idea’s rating was upgraded by UBS from Neutral to Buy, with a new price target of ₹18.
Sensex and Nifty
For the quarter ending in March 2024, Prakash Pipes recorded a net profit of ₹25.36 crore, a 9.99% increase over the same period the previous year. Hindudalco Industries had a 0.92% increase in total net profit to ₹3,174 crore over the prior year. Consolidated net profit for Ashok Leyland increased by 1.48% to ₹933.69 crore over the prior year.
The BSE Sensex increased by 0.034% to 75,442, while the NSE Nifty increased by 0.7% to 22,982. 3,842 equities were exchanged in total; 1,876 of them were in the green while 1,826 were in the red.
Ten new products were launched by Coromandel International Limited with the goals of increasing crop productivity, reducing pest infestations, and advancing sustainable farming methods. More ₹20 crore worth of export orders for lab-grown diamond-shaded gold jewelry were received by Goldiam International.
On the NSE, shares of Aegis Logistics increased by 7.34%, closing at ₹676.35. After a US short-seller report accused the business of manipulating stocks and improperly using tax havens, Adani Enterprises shares recovered to levels last seen in January 2023. The collective market worth of the group lost up to $150 billion.
With zero 483 findings, Gland Pharma reported that the USFDA had concluded its inspection of its API Facility at JNPC, Visakhapatnam. The introduction of MemUp, a hormone replacement treatment (HRT) that combines bioidentical progesterone and estradiol in a daily oral capsule approved by the USFDA, caused shares of Jagsonpal Pharmaceuticals Ltd to rise by 4.71%.
